M

Monte Rosa Therapeutics Inc
NASDAQ:GLUE

Watchlist Manager
Monte Rosa Therapeutics Inc
NASDAQ:GLUE
Watchlist
Price: 17.29 USD -1.98% Market Closed
Market Cap: 1.1B USD

Wall Street
Price Targets

GLUE Price Targets Summary
Monte Rosa Therapeutics Inc

Wall Street analysts forecast GLUE stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for GLUE is 21.78 USD with a low forecast of 16.16 USD and a high forecast of 28.88 USD.

Lowest
Price Target
16.16 USD
7% Downside
Average
Price Target
21.78 USD
26% Upside
Highest
Price Target
28.88 USD
67% Upside
Monte Rosa Therapeutics Inc Competitors:
Price Targets
MIRM
Mirum Pharmaceuticals Inc
32% Upside
7774
Japan Tissue Engineering Co Ltd
113% Upside
TLX
Telix Pharmaceuticals Ltd
131% Upside
87S
Roivant Sciences Ltd
12% Upside
6855
Ascentage Pharma Group International
97% Upside
IPH
Innate Pharma SA
223% Upside
CAPR
Capricor Therapeutics Inc
70% Upside
TRDA
Entrada Therapeutics Inc
62% Upside

Revenue
Forecast

Revenue Estimate
Monte Rosa Therapeutics Inc

The compound annual growth rate of Monte Rosa Therapeutics Inc's revenue for the next 4 years is -11%.

N/A
Past Growth
-11%
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

Operating Income
Forecast

Operating Income Estimate
Monte Rosa Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
1%
Average Beat

Net Income
Forecast

Net Income Estimate
Monte Rosa Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-28%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is GLUE's stock price target?
Price Target
21.78 USD

According to Wall Street analysts, the average 1-year price target for GLUE is 21.78 USD with a low forecast of 16.16 USD and a high forecast of 28.88 USD.

What is Monte Rosa Therapeutics Inc's Revenue forecast?
Projected CAGR
-11%

The compound annual growth rate of Monte Rosa Therapeutics Inc's revenue for the next 4 years is -11%.

Back to Top